Skip to main content
. 2018 Jan 19;9(11):9808–9824. doi: 10.18632/oncotarget.24275

Figure 9. RRD-251 enhances D3-induced interactions of GSK-3 with RXR and VDR.

Figure 9

RXRα and VDR nuclear expression were assessed by Western blotting, and nuclear interactions with GSK-3 were assessed by immunoprecipitation. Nuclear lysates collected 48 hours after treatment and were resolved in 12% polyacrylamide gels. 25 μg of protein was loaded per well for Western blotting. (A) D3 promotes increased nuclear expression of RXRα with no further enhancement in RRD-251 co-treated samples. (B-C) An RXRα antibody was used as the precipitating antibody and the resulting blot was probed with total GSK-3α/β. D3 promotes a decrease in interaction between RXRα and GSK-3α/β. RRD-251 co-treatment further diminishes the interaction. (D) D3 promotes increased nuclear expression of VDR with no further enhancement in RRD-251 co-treated samples. (E-F) A VDR antibody was used as the precipitating antibody and the resulting blot was probed with GSK-3α/β. D3 alone promotes only a small increase in interactions between VDR and GSK-3α/β, which is much augmented by co-treatment.